

Opioid Antagonist Drug-North America Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/O0E28C5BDCCEN.html>

Date: February 2018

Pages: 137

Price: US\$ 3,480.00 (Single User License)

ID: O0E28C5BDCCEN

Abstracts

Report Summary

Opioid Antagonist Drug-North America Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Opioid Antagonist Drug industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole North America and Regional Market Size of Opioid Antagonist Drug 2013-2017, and development forecast 2018-2023

Main market players of Opioid Antagonist Drug in North America, with company and product introduction, position in the Opioid Antagonist Drug market

Market status and development trend of Opioid Antagonist Drug by types and applications

Cost and profit status of Opioid Antagonist Drug, and marketing status

Market growth drivers and challenges

The report segments the North America Opioid Antagonist Drug market as:

North America Opioid Antagonist Drug Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

United States

Canada

Mexico

North America Opioid Antagonist Drug Market: Product Type Segment Analysis
(Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Tablet
Injection

North America Opioid Antagonist Drug Market: Application Segment Analysis
(Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospital
Medical Center

North America Opioid Antagonist Drug Market: Players Segment Analysis (Company and Product introduction, Opioid Antagonist Drug Sales Volume, Revenue, Price and Gross Margin):

Pfizer
Conatus Pharmaceuticals
Novartis
Intercept Pharmaceuticals
Allergan
Immuron
Takeda
Gilead Sciences
Genfit

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF OPIOID ANTAGONIST DRUG

- 1.1 Definition of Opioid Antagonist Drug in This Report
- 1.2 Commercial Types of Opioid Antagonist Drug
 - 1.2.1 Tablet
 - 1.2.2 Injection
- 1.3 Downstream Application of Opioid Antagonist Drug
 - 1.3.1 Hospital
 - 1.3.2 Medical Center
- 1.4 Development History of Opioid Antagonist Drug
- 1.5 Market Status and Trend of Opioid Antagonist Drug 2013-2023
 - 1.5.1 North America Opioid Antagonist Drug Market Status and Trend 2013-2023
 - 1.5.2 Regional Opioid Antagonist Drug Market Status and Trend 2013-2023

CHAPTER 2 NORTH AMERICA MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Opioid Antagonist Drug in North America 2013-2017
- 2.2 Consumption Market of Opioid Antagonist Drug in North America by Regions
 - 2.2.1 Consumption Volume of Opioid Antagonist Drug in North America by Regions
 - 2.2.2 Revenue of Opioid Antagonist Drug in North America by Regions
- 2.3 Market Analysis of Opioid Antagonist Drug in North America by Regions
 - 2.3.1 Market Analysis of Opioid Antagonist Drug in United States 2013-2017
 - 2.3.2 Market Analysis of Opioid Antagonist Drug in Canada 2013-2017
 - 2.3.3 Market Analysis of Opioid Antagonist Drug in Mexico 2013-2017
- 2.4 Market Development Forecast of Opioid Antagonist Drug in North America 2018-2023
 - 2.4.1 Market Development Forecast of Opioid Antagonist Drug in North America 2018-2023
 - 2.4.2 Market Development Forecast of Opioid Antagonist Drug by Regions 2018-2023

CHAPTER 3 NORTH AMERICA MARKET STATUS AND FORECAST BY TYPES

- 3.1 Whole North America Market Status by Types
 - 3.1.1 Consumption Volume of Opioid Antagonist Drug in North America by Types
 - 3.1.2 Revenue of Opioid Antagonist Drug in North America by Types
- 3.2 North America Market Status by Types in Major Countries
 - 3.2.1 Market Status by Types in United States

- 3.2.2 Market Status by Types in Canada
- 3.2.3 Market Status by Types in Mexico
- 3.3 Market Forecast of Opioid Antagonist Drug in North America by Types

CHAPTER 4 NORTH AMERICA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Demand Volume of Opioid Antagonist Drug in North America by Downstream Industry
- 4.2 Demand Volume of Opioid Antagonist Drug by Downstream Industry in Major Countries
 - 4.2.1 Demand Volume of Opioid Antagonist Drug by Downstream Industry in United States
 - 4.2.2 Demand Volume of Opioid Antagonist Drug by Downstream Industry in Canada
 - 4.2.3 Demand Volume of Opioid Antagonist Drug by Downstream Industry in Mexico
- 4.3 Market Forecast of Opioid Antagonist Drug in North America by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF OPIOID ANTAGONIST DRUG

- 5.1 North America Economy Situation and Trend Overview
- 5.2 Opioid Antagonist Drug Downstream Industry Situation and Trend Overview

CHAPTER 6 OPIOID ANTAGONIST DRUG MARKET COMPETITION STATUS BY MAJOR PLAYERS IN NORTH AMERICA

- 6.1 Sales Volume of Opioid Antagonist Drug in North America by Major Players
- 6.2 Revenue of Opioid Antagonist Drug in North America by Major Players
- 6.3 Basic Information of Opioid Antagonist Drug by Major Players
 - 6.3.1 Headquarters Location and Established Time of Opioid Antagonist Drug Major Players
 - 6.3.2 Employees and Revenue Level of Opioid Antagonist Drug Major Players
- 6.4 Market Competition News and Trend
 - 6.4.1 Merger, Consolidation or Acquisition News
 - 6.4.2 Investment or Disinvestment News
 - 6.4.3 New Product Development and Launch

CHAPTER 7 OPIOID ANTAGONIST DRUG MAJOR MANUFACTURERS

INTRODUCTION AND MARKET DATA

7.1 Pfizer

7.1.1 Company profile

7.1.2 Representative Opioid Antagonist Drug Product

7.1.3 Opioid Antagonist Drug Sales, Revenue, Price and Gross Margin of Pfizer

7.2 Conatus Pharmaceuticals

7.2.1 Company profile

7.2.2 Representative Opioid Antagonist Drug Product

7.2.3 Opioid Antagonist Drug Sales, Revenue, Price and Gross Margin of Conatus Pharmaceuticals

7.3 Novartis

7.3.1 Company profile

7.3.2 Representative Opioid Antagonist Drug Product

7.3.3 Opioid Antagonist Drug Sales, Revenue, Price and Gross Margin of Novartis

7.4 Intercept Pharmaceuticals

7.4.1 Company profile

7.4.2 Representative Opioid Antagonist Drug Product

7.4.3 Opioid Antagonist Drug Sales, Revenue, Price and Gross Margin of Intercept Pharmaceuticals

7.5 Allergan

7.5.1 Company profile

7.5.2 Representative Opioid Antagonist Drug Product

7.5.3 Opioid Antagonist Drug Sales, Revenue, Price and Gross Margin of Allergan

7.6 Immuron

7.6.1 Company profile

7.6.2 Representative Opioid Antagonist Drug Product

7.6.3 Opioid Antagonist Drug Sales, Revenue, Price and Gross Margin of Immuron

7.7 Takeda

7.7.1 Company profile

7.7.2 Representative Opioid Antagonist Drug Product

7.7.3 Opioid Antagonist Drug Sales, Revenue, Price and Gross Margin of Takeda

7.8 Gilead Sciences

7.8.1 Company profile

7.8.2 Representative Opioid Antagonist Drug Product

7.8.3 Opioid Antagonist Drug Sales, Revenue, Price and Gross Margin of Gilead Sciences

7.9 Genfit

7.9.1 Company profile

7.9.2 Representative Opioid Antagonist Drug Product

7.9.3 Opioid Antagonist Drug Sales, Revenue, Price and Gross Margin of Genfit

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF OPIOID ANTAGONIST DRUG

8.1 Industry Chain of Opioid Antagonist Drug

8.2 Upstream Market and Representative Companies Analysis

8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF OPIOID ANTAGONIST DRUG

9.1 Cost Structure Analysis of Opioid Antagonist Drug

9.2 Raw Materials Cost Analysis of Opioid Antagonist Drug

9.3 Labor Cost Analysis of Opioid Antagonist Drug

9.4 Manufacturing Expenses Analysis of Opioid Antagonist Drug

CHAPTER 10 MARKETING STATUS ANALYSIS OF OPIOID ANTAGONIST DRUG

10.1 Marketing Channel

10.1.1 Direct Marketing

10.1.2 Indirect Marketing

10.1.3 Marketing Channel Development Trend

10.2 Market Positioning

10.2.1 Pricing Strategy

10.2.2 Brand Strategy

10.2.3 Target Client

10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

12.1 Methodology/Research Approach

12.1.1 Research Programs/Design

12.1.2 Market Size Estimation

12.1.3 Market Breakdown and Data Triangulation

12.2 Data Source

12.2.1 Secondary Sources

12.2.2 Primary Sources

12.3 Reference

I would like to order

Product name: Opioid Antagonist Drug-North America Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/O0E28C5BDCCEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/O0E28C5BDCCEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970